The burgeoning landscape of medication for obesity and type 2 metabolic disorder is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant variations in their pharmacological profiles and clinical trial results are emerging. Retatrutide,

Retaglutide and tirzepatide represent cutting-edge class of medications known as dual GLP-1 and GIP agonists. These agents influence both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that play a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones